Evidence map›Paper›PMID 33675382›Full record

ArticleAbdominal radiology (New York)2021

Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis.

Kanehiko Suwa, Toshihito Seki, Kazunori Aoi, Masao Yamashina, Miki Murata, Noriyo Yamashiki, Akiyoshi Nishio, Masaaki Shimatani, Makoto Naganuma

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Abdominal radiology (New York), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06096896 (The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06096896 active not recruitingnot on this mapstarted 2023, after this paper: background citation

The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study

TypeobservationalSponsorShandong Provincial HospitalRan2023 to 2030Enrolled334ConditionsEarly Hepatocellular CarcinomaArmsMWA
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Computational Modeling of Microwave Tumor Ablation.Bioengineering (Basel, Switzerland) · 2022
    Review
  12. Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists.Radiographics : a review publication of the Radiological Society of North America, Inc · 2022
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kanehiko SuwaThe Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1 Shimmachi, Hirakata, Osaka, 573-1101, Japan. suwakan@takii.kmu.ac.jp.ORCID http://orcid.org/0000-0003-1986-7061
Toshihito SekiKansai Medical University Medical Center, Liver Disease Center, 10-15 Fumizonocho, Moriguchi, Osaka, 570-8507, Japan.
Kazunori AoiThe Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1 Shimmachi, Hirakata, Osaka, 573-1101, Japan.
Masao YamashinaThe Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1 Shimmachi, Hirakata, Osaka, 573-1101, Japan.
Miki MurataThe Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1 Shimmachi, Hirakata, Osaka, 573-1101, Japan.
Noriyo YamashikiThe Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1 Shimmachi, Hirakata, Osaka, 573-1101, Japan.
Akiyoshi NishioThe Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1 Shimmachi, Hirakata, Osaka, 573-1101, Japan.
Masaaki ShimataniThe Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1 Shimmachi, Hirakata, Osaka, 573-1101, Japan.
Makoto NaganumaThe Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, 2-3-1 Shimmachi, Hirakata, Osaka, 573-1101, Japan.
Kansai Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the efficacy and safety of radiofrequency ablation (RFA) and new-generation microwave ablation (MWA) for the treatment of hepatocellular carcinoma (HCC).

methodsThe propensity score matching method was applied to patients with HCC treated with MWA (93 patients) or RFA (156 patients) at a single institution from January 2014 to April 2020. The local tumor progression (LTP), intrahepatic distant recurrence (IDR), and recurrence-free survival (RFS) of the two matched therapies were analyzed using the Kaplan-Meier method. Cox proportional hazard models were used to identify risk factors for LTP and RFS. The therapeutic effects and complications of the two treatments were also compared.

resultsThe LTP, IDR, and RFS of MWA and RFA were equivalent (LTP: hazard ratio [HR] = 0.87; 95% confidence interval [95% CI] 0.36- 2.07; P = 0.746, IDR: HR = 1.03; 95% CI 0.61-1.73; P = 0.890, RFS: HR = 1.15; 95% CI 0.69-1.91; P = 0.566). Para-vessel lesions was the only risk factor for LTP, whereas age, previous treatment, Albumin-Bilirubin score, and tumor diameter were risk factors for RFS. On the other hand, the ablation time per nodule (6.79 ± 2.73 and 9.21 ± 4.90 min; P = 0.008) and number of sessions per nodule required to achieve technical success (1.16 ± 0.39 and 1.34 ± 0.57; P = 0.009) were significantly lower in MWA than in RFA. The major complication rate of MWA and RFA was also equivalent.

conclusionMWA and RFA have similar therapeutic effects and safety, although MWA has advantages over RFA regarding efficacy, including shorter ablation time and fewer sessions required.

Indexed as

Carcinoma, HepatocellularCatheter AblationLiver NeoplasmsRadiofrequency AblationHumansMicrowavesNeoplasm Recurrence, LocalPropensity ScoreRetrospective StudiesTreatment OutcomeHepatocellular carcinomaLocal tumor progressionMicrowave ablationRadiofrequency ablationRecurrence-free survival

Identifiers

PMID33675382
PMCPMC8286931
OpenAlexW3133753979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.